Pharmaceuticals, Biotechnology and Life Sciences
Shionogi presented data suggest cefiderocol shows a high potential for treating infections caused by themost difficult to treat Gram-negative (GN) bacteria collected fromacross Europe, including multidrug-resistant strains.
United States Foodand Drug Administration (FDA) has cleared the Company’s lead productcandidate, PLENITY (Gelesis100), as an aid in weight management inadults with a Body Mass Index (BMI) of 25–40 kg/m2, when usedin conjunction with diet and exercise.
Dr.Reddy’s has entered into a definitive agreement toacquire a portfolio of 42 approved, non-marketed Abbreviated New DrugApplications (ANDAs) in the U.S.
ASPECT-NP Clinical Trial Results Demonstrated Non-Inferiority of ZERBAXA to Meropenem for Treating Ventilated Nosocomial Pneumonia in Primary and Key Secondary…
ASPECT-NP Clinical Trial Results Demonstrated Non-Inferiority of ZERBAXA to Meropenem for Treating Ventilated Nosocomial Pneumonia in Primary and Key Secondary…
The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data – – –…
Novel therascreen® FGFR RGQ RT-PCR Kit will aid in identifying patients eligible for treatment with BALVERSA™ (erdafitinib), developed by Janssen…
Further Milestone from Janssen on NDA Approval by the US FDA of BALVERSA™ (erdafitinib) for the Treatment of Urothelial Cancer…
DUBLIN–(BUSINESS WIRE)–The “Cansidas – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Cansidas – Drug Insight, 2019 highlights…
DUBLIN–(BUSINESS WIRE)–The “Zactos – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Zactos – Drug Insight, 2019 highlights…